2
Clinical Trials associated with LX-102(Amarin Neuroscience)A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
A Dose-Escalation Study of LX102 Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD)
The goal of this study is to evaluate the safety and efficacy of LX102 gene therapy for nAMD.
100 Clinical Results associated with LX-102(Amarin Neuroscience)
100 Translational Medicine associated with LX-102(Amarin Neuroscience)
100 Patents (Medical) associated with LX-102(Amarin Neuroscience)
100 Deals associated with LX-102(Amarin Neuroscience)